PEDIATRICS Vol. 90 No. 1 July 1992, pp. 108-109
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WALKER, S. B.
Right arrow Articles by TATTONI, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WALKER, S. B.
Right arrow Articles by TATTONI, D. S.

Systemic Reaction to Human Growth Hormone Treated With Acute Desensitization

SUSANNAH B. WALKER MD1, MICHAEL E. WEISS MD2, and DIANA S. TATTONI MD1

1 Department of Pediatrics, University of Washington, Seattle, Washington
2 Department of Medicine, University of Washington, Seattle, Washington

Recombinant DNA technology has led to increased production and widespread use of recombinant growth hormone. Systemic allergic reactions to recombinant growth hormone such as urticaria, angioedema, or anaphylaxis have not been described in the literature. We report a patient who developed generalized urticaria from recombinant human growth hormone (Humatrope, Eli Lilly and Company) in whom we successfully desensitized to growth hormone using a protocol modified from an insulin desensitization schedule.1

CASE REPORT

A 12-year-old girl with hypopituitarism and short stature had been treated with 2 mg to 5 mg of Humatrope (depending on her weight and responsiveness to treatment) intramuscularly 6 days a week for 3 years without any problems.

Submitted on September 27, 1991
Accepted on December 12, 1992